相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase III Study of Gefitinib 250 Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
J. Simon W. Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A. A. M. van der Veldt et al.
BRITISH JOURNAL OF CANCER (2008)
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
Keith T. Flaherty et al.
CANCER BIOLOGY & THERAPY (2008)
Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)
N. W. Choong et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma
Olwen M. Hahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Transvascular and interstitial transport in rat hepatocellular carcinomas: Dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents
Nicolas Michoux et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
Christine Elser et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
E. Winquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
Matthew G. Fury et al.
INVESTIGATIONAL NEW DRUGS (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities
J. G. Christensen
ANNALS OF ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Comparative study iinto the robustness of compartmental modeling and model-free analysis in DCE-MRI studies
C Roberts et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
X León et al.
CLINICAL ONCOLOGY (2005)
Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma
P Marzola et al.
CLINICAL CANCER RESEARCH (2005)
Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapy
MS Anscher et al.
SEMINARS IN ONCOLOGY (2005)
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis
PA Kyzas et al.
CLINICAL CANCER RESEARCH (2005)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck
C Neuchrist et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2003)
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Estimates of the world-wide prevalence of cancer for 25 sites in the adult population
P Pisani et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck
C Neuchrist et al.
LARYNGOSCOPE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Serum levels of vascular endothelial growth factor in patients with head and neck cancer
F Riedel et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
